CD274 and renal cell carcinoma: A recently published study on advanced RCC involving 443 patients who received avelumab plus axitinib and 444 patients who were treated with sunitinib alone (NCT02684006) showed that avelumab plus axitinib significantly improved the PFS by 5–6 months regardless of the PD-L1 positive group or the overall population as compared with sunitinib alone.